Connect Antibody

Function to Clinical

Outcomes with Immune

Profiling



Connect Antibody Fc Effector Function to Clinical Outcomes with Immune Profiling

Our technology integrates a broad suite of biophysical and functional assays to comprehensively profile immune responses. Using multidimensional data and targeted analysis, we help teams assess effector function, understand mechanism of action, and guide development decisions.

Technology Designed To

Technology Designed To

  • Capture antibody function and structure in physiologically relevant conditions


  • Enable reproducible, quantitative comparisons across candidates


  • Translate functional insights into data packages that inform preclinical and clinical decisions
  • Capture antibody function and structure in physiologically relevant conditions


  • Enable reproducible, quantitative comparisons across candidates


  • Translate functional insights into data packages that inform preclinical and clinical decisions

Technology Designed To

Technology Designed To

  • Capture antibody function and structure in physiologically relevant conditions


  • Enable reproducible, quantitative comparisons across candidates


  • Translate functional insights into data packages that inform preclinical and clinical decisions

Integrate a broad suite of biophysical and functional assays to comprehensively profile the Fc function of immune effectors. Using multidimensional data and targeted analysis, we help teams assess effector function, understand mechanism of action, and guide development decisions.


  • Capture antibody function and structure in physiologically relevant conditions


  • Enable reproducible, quantitative comparisons across candidates


  • Translate functional insights into data packages that inform preclinical and clinical decisions

The Suite of 15 Functional and

Biophysical Assays

Eleven assays interrogate antibody function, and four assays describe antibody biophysical structure, linking the specified effector function(s) to the biophysical structure of the Fc region of the antibody.

*Click on each assay for a more detailed description.

The Suite of 15 Functional and

Biophysical Assays

The Suite of 15 Functional

and Biophysical Assays

Eleven assays interrogate antibody function, while four biophysical assays characterize the Fc region’s structure, together linking antibody function to Fc biophysical properties.

*Click on each assay for a more detailed description.

Download Assay List

Key Effectors and Components of Fc Function

We continue to expand the assay suite in response to emerging needs across immunotherapy and vaccine development, particularly as therapeutic formats become more complex and mechanism-specific.


  • Functional profiling across multiple FcγR-expressing cell types
  • Quantification of antibody-mediated phagocytosis, cytotoxicity, and cytokine induction
  • Assessment of complement activation pathways (excluding complement lysis)
  • Exploration of less conventional interactions, including mucin binding.


This framework provides a scalable foundation for studying both canonical and emerging mechanisms of action within the Fc domain.

GCLP-Accredited

Good Clinical Laboratory Practice

We operate under the standards of Good Clinical Laboratory Practice (GCLP), ensuring the generation of high-quality, reliable laboratory data to support clinical trials.


By applying GLP principles to clinical sample analysis while maintaining alignment with GCP objectives, we uphold the integrity, accuracy, and reproducibility of every data point we produce. Our adherence to GCLP guidelines reinforces patient safety and empowers regulatory decision-making.


By embedding GCLP into our daily operations, we deliver the precision and transparency your clinical programs demand.

GCLP-Accredited

Good Clinical Laboratory Practice


We operate under the standards of Good Clinical Laboratory Practice (GCLP), ensuring the generation of high-quality, reliable laboratory data to support clinical trials.


By applying GLP principles to clinical sample analysis while maintaining alignment with GCP objectives, we uphold the integrity, accuracy, and reproducibility of every data point we produce. Our adherence to GCLP guidelines reinforces patient safety and empowers regulatory decision-making.


By embedding GCLP into our daily operations, we deliver the precision and transparency your clinical programs demand.

TAILORED FOR ANTIBODY THERAPEUTICS AND VACCINES

Our technology is designed to support a broad range of discovery and development efforts for both antibodies and vaccines.

When More Isn’t Better: Why Antibody Titers Alone Don’t Predict Protection


  • Higher neutralization titer doesn’t always mean better protection: A study on the live-attenuated influenza vaccine shows no correlation between increased antibody levels and improved immunity.

  • Neutralization titer increase does not guarantee influenza protection: Despite a tenfold rise in titer, the rate of influenza positivity remained unchanged.

  • Functional assays are essential: Measuring antibody levels alone isn’t enough; functional assays are needed to assess true immune protection.

LEARN MORE

CD20 mAbs: How Fc Design Shapes Complement-Mediated Function


  • Comparative Functional Profiling of CD20 mAbs: Rituximab, Ofatumumab, and Obinutuzumab exhibit distinct profiles in C1q binding, ADCD, and CDC activities, enabling developers to evaluate complement-related mechanisms across therapeutic antibodies targeting the same antigen.
  • Ofatumumab Shows Highest Complement Activation Potential: Among the three CD20 mAbs, Ofatumumab demonstrates the strongest C1q binding and ADCD response, suggesting enhanced CDC potency and potential for superior direct complement-mediated cytotoxicity.
  • Obinutuzumab’s Fc Engineering Impacts Complement Function: Obinutuzumab, an afucosylated Type II mAb, shows significantly reduced C1q binding and CDC despite strong ADCP, emphasizing the importance of Fc design choices on effector function profiles.

LEARN MORE